Figure 7.

In vivo efficacy and PK of PF-07062119. (a) Mean serum pharmacokinetic profiles of GUCY2C-0247, PF‑06929607 and PF-07062119 in cynomolgus monkeys following single dose IV administration at 30 µg/kg and 60 µg/kg. (b) Results of non-compartmental analysis of the observed PK (0–168 hrs) of GUCY2C-0247 and PF‑07062119. Note that apparent CL estimates may be overestimated, and half-life may be underestimated for PF‑07062119 due to the limited observation period. (c) In vivo efficacy LS1034 adoptive transfer xenograft model demonstrates potent activity down to 0.1 mg/kg for PF-07062119 (n = 10 animals/group). Data shown from one donor. Similar results were obtained from separate experiments with other donor T cells